Burning rock's minimal residual disease (mrd) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the cancer cell

Guangzhou, china, sept. 07, 2023 (globe newswire) -- burning rock biotech limited (nasdaq: bnr and lse: bnr, the “company” or “burning rock”) is delighted to announce that our personalized minimal residual disease (mrd) product, cancatch® (prophettm panel), was enrolled in a prospective observational study (medal, methylation based dynamic analysis for lung cancer, nct03634826).
BNR Ratings Summary
BNR Quant Ranking